Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors

Inclusion Criteria: 1. The patient understands and voluntarily signs the informed consent form, and is expected to complete the follow-up examination and treatment of the study procedures; 2. Age 18-75 years old, gender unlimited; 3. Tumor patients who have positive expression of CDH17 target in tumor tissues measured by immunohistochemistry (IHC) in a laboratory approved by the partner, and have no standard therapy or are ineffective or not suitable for standard treatment; 4. Have at least one extracranial measurable lesion according to RECIST 1.1 criteria; 5. Estimated survival ≥ 12 weeks; 6. Baseline ECOG (Eastern Cooperative Oncology Group) score ≤ 1 point; 7. The patient has recovered from the toxicity of the prior treatment, i.e., CTCAE toxicity grade \< 2 (unless the abnormality is related to the tumor or is stable as judged by the investigator and has little impact on safety or efficacy); 8. Venous access could be established; without contraindications of apheresis. Exclusion Criteria: 1. Patients with prior or current other malignancies; 2. Presence of brain metastases and clinically significant central nervous system disease; 3. Prior antitumor therapy (prior to blood collection for CAR-T preparation) : targeted therapy, epigenetic therapy, or investigational drug therapy within 14 days or at least 5 half-lives, whichever is shorter; 4. Subjects with positive HBsAg or HBcAb positive and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive; HIV antibody positive; CMV DNA titer is higher than the lower limit of detection of the research institution; EBV DNA titer is higher than the lower limit of detection of the research institution 5. Those who have a positive sputum smear and T-cell test for tuberculosis infection; 6. Patients with objective evidence of a history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, and severe impairment of lung function, both past and present; 7. Patients have a severe allergic history; 8. Patients with severe heart disease or uncontrollable refractory hypertension; 9. Patients with severe liver and kidney dysfunction or consciousness disorders; 10. Active autoimmune or inflammatory diseases of the nervous system; 11. Uncontrolled infections that need antibiotics treatment; 12. Live attenuated vaccine within 4 weeks before screening; 13. Alcoholics or persons with a history of drug abuse; 14. Pregnant or Lactating Women; Patients and his or her spouse have a fertility plan within two years after CAR-T cell infusion; 15. Any unsuitable to participate in this trial judged by the investigator.